Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

Nicole DeFeudis

Editor

Viridian Therapeutics’ stock jumped Monday after the company unveiled another Phase 3 look at its potential competitor to Amgen’s Tepezza in thyroid eye disease. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

Nicole DeFeudis

Editor

Sign up to read this article for free.

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Biohaven’s protein degrader cuts antibodies by 60%

Virid­i­an read­ies for Te­pez­za ri­val­ry with new Phase 3 da­ta in thy­roid eye dis­ease

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

Bio­haven’s pro­tein de­grad­er cuts an­ti­bod­ies by 60%

Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Biohaven’s protein degrader cuts antibodies by 60%